PL3626270T3 - Leczenie chorób sercowo-naczyniowych - Google Patents

Leczenie chorób sercowo-naczyniowych

Info

Publication number: PL3626270T3
Authority: PL; Poland
Prior art keywords: treatment; cardiovascular diseases; cardiovascular; diseases
Prior art date: 2013-08-26

Application number

PL19202854.6T

Other languages

English (en)

Inventor

Victor Chengwei Shi

Martin Lefkowitz

Adel Remond RIZKALA

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-26

Filing date

2014-08-26

Publication date

2024-04-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3626270(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-08-26 Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en

2014-08-26 Application filed by Novartis Ag filed Critical Novartis Ag

2024-04-08 Publication of PL3626270T3 publication Critical patent/PL3626270T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

PL19202854.6T 2013-08-26 2014-08-26 Leczenie chorób sercowo-naczyniowych PL3626270T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/US2013/056680 WO2015030711A1 (en)	2013-08-26	2013-08-26	New use
US201461972933P	2014-03-31	2014-03-31

Publications (1)

Publication Number	Publication Date
PL3626270T3 true PL3626270T3 (pl)	2024-04-08

Family

ID=51494327

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL23202190.7T PL4321157T3 (pl)	2013-08-26	2014-08-26	Nowe zastosowanie kombinacji blokera receptora angiotensyny (arb) z inhibitorem neutralnej endopeptydazy (nepi)
PL14761702T PL3038654T3 (pl)	2013-08-26	2014-08-26	Nowe zastosowanie
PL19202854.6T PL3626270T3 (pl)	2013-08-26	2014-08-26	Leczenie chorób sercowo-naczyniowych

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL23202190.7T PL4321157T3 (pl)	2013-08-26	2014-08-26	Nowe zastosowanie kombinacji blokera receptora angiotensyny (arb) z inhibitorem neutralnej endopeptydazy (nepi)
PL14761702T PL3038654T3 (pl)	2013-08-26	2014-08-26	Nowe zastosowanie

Country Status (16)

Country	Link
US (2)	US20160213646A1 (pl)
EP (4)	EP4321157B1 (pl)
JP (1)	JP6097888B2 (pl)
CY (1)	CY1122531T1 (pl)
DK (3)	DK4321157T3 (pl)
ES (3)	ES3001196T3 (pl)
FI (2)	FI3626270T3 (pl)
HR (3)	HRP20241763T1 (pl)
HU (3)	HUE047186T2 (pl)
LT (3)	LT3038654T (pl)
PL (3)	PL4321157T3 (pl)
PT (3)	PT3626270T (pl)
RS (3)	RS59816B1 (pl)
SI (3)	SI3038654T1 (pl)
SM (1)	SMT202500001T1 (pl)
WO (1)	WO2015028941A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS59816B1 (sr)	2013-08-26	2020-02-28	Novartis Ag	Nova primena
WO2016125123A1 (en) *	2015-02-06	2016-08-11	Mylan Laboratories Limited	Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
JP2018516267A (ja) *	2015-05-29	2018-06-21	ノバルティスアーゲー	代謝性疾患を治療するためのサクビトリルおよびバルサルタン
CN106309388A (zh) *	2015-06-30	2017-01-11	深圳信立泰药业股份有限公司	一种用于心衰治疗的药物组合物及其制备方法
CN107510653A (zh) *	2016-06-17	2017-12-26	常州爱诺新睿医药技术有限公司	一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
WO2017036420A1 (zh) *	2015-09-06	2017-03-09	常州方楠医药技术有限公司	含沙库比曲和缬沙坦的药用组合物及其制备方法
CN106491600A (zh) *	2015-09-06	2017-03-15	常州方楠医药技术有限公司	无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
WO2017042700A1 (en) *	2015-09-07	2017-03-16	Sun Pharmaceutical Industries Limited	Solid forms of valsartan and sacubitril
CN106580908A (zh) *	2015-10-16	2017-04-26	深圳信立泰药业股份有限公司	一种用于心血管疾病治疗的口服制剂及其制备方法
CN105330609B (zh) *	2015-12-07	2017-12-22	南京正大天晴制药有限公司	一种制备lcz696的方法
WO2017134597A1 (en)	2016-02-03	2017-08-10	Novartis Ag	Galenic formulations of organic compounds
CN106176681A (zh) *	2016-08-25	2016-12-07	泰力特医药（湖北）有限公司	一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
US11382866B2 (en)	2017-07-06	2022-07-12	Mankind Pharma Ltd.	Fixed dose pharmaceutical composition of valsartan and sacubitril
KR20210032437A (ko)	2018-08-23	2021-03-24	노파르티스 아게	심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en)	2018-08-24	2020-02-27	Novartis Ag	New drug combinations
CN115487175B (zh) *	2019-09-20	2024-05-14	深圳信立泰药业股份有限公司	血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE59107440D1 (de)	1990-02-19	1996-04-04	Ciba Geigy Ag	Acylverbindungen
US5217996A (en)	1992-01-22	1993-06-08	Ciba-Geigy Corporation	Biaryl substituted 4-amino-butyric acid amides
ES2200310T3 (es) *	1997-01-10	2004-03-01	MERCK & CO., INC.	Uso de antagonistas de la angiotensina ii losartan y exp-3174 en el tratamiento de la insuficiencia cardiaca sintomatica.
KR20100057704A (ko) *	2002-01-17	2010-05-31	노파르티스 아게	발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
US20070054947A1 (en) *	2003-05-16	2007-03-08	Cohn Jay N	Pharmaceutical composition comprising valsartan
AR057882A1 (es) *	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
MX2010004930A (es)	2007-11-06	2010-05-27	Novartis Ag	Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep).
US20100143351A1 (en)	2008-11-22	2010-06-10	Genentech, Inc.	Anti-Angiogenesis Therapy for the Treatment of Breast Cancer
CN103079554A (zh)	2010-08-24	2013-05-01	诺华有限公司	在接受抗凝血剂疗法的哺乳动物中治疗高血压和/或预防或治疗心力衰竭
CA2882771C (en)	2012-08-24	2021-02-23	Novartis Ag	Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
WO2015030711A1 (en) *	2013-08-26	2015-03-05	Novartis Ag	New use
RS59816B1 (sr)	2013-08-26	2020-02-28	Novartis Ag	Nova primena

2014
- 2014-08-26 RS RS20200047A patent/RS59816B1/sr unknown
- 2014-08-26 FI FIEP19202854.6T patent/FI3626270T3/fi active
- 2014-08-26 SI SI201431464T patent/SI3038654T1/sl unknown
- 2014-08-26 SI SI201432099T patent/SI4321157T1/sl unknown
- 2014-08-26 EP EP23202190.7A patent/EP4321157B1/en active Active
- 2014-08-26 PL PL23202190.7T patent/PL4321157T3/pl unknown
- 2014-08-26 ES ES23202190T patent/ES3001196T3/es active Active
- 2014-08-26 WO PCT/IB2014/064074 patent/WO2015028941A1/en not_active Ceased
- 2014-08-26 HR HRP20241763TT patent/HRP20241763T1/hr unknown
- 2014-08-26 US US14/914,005 patent/US20160213646A1/en not_active Abandoned
- 2014-08-26 PT PT192028546T patent/PT3626270T/pt unknown
- 2014-08-26 PT PT147617021T patent/PT3038654T/pt unknown
- 2014-08-26 DK DK23202190.7T patent/DK4321157T3/da active
- 2014-08-26 LT LTEP14761702.1T patent/LT3038654T/lt unknown
- 2014-08-26 SI SI201432059T patent/SI3626270T1/sl unknown
- 2014-08-26 RS RS20240031A patent/RS65037B1/sr unknown
- 2014-08-26 LT LTEP23202190.7T patent/LT4321157T/lt unknown
- 2014-08-26 LT LTEP19202854.6T patent/LT3626270T/lt unknown
- 2014-08-26 HU HUE14761702A patent/HUE047186T2/hu unknown
- 2014-08-26 JP JP2016537414A patent/JP6097888B2/ja active Active
- 2014-08-26 FI FIEP23202190.7T patent/FI4321157T3/fi active
- 2014-08-26 ES ES14761702T patent/ES2767084T3/es active Active
- 2014-08-26 ES ES19202854T patent/ES2968541T3/es active Active
- 2014-08-26 PT PT232021907T patent/PT4321157T/pt unknown
- 2014-08-26 EP EP14761702.1A patent/EP3038654B1/en not_active Revoked
- 2014-08-26 SM SM20250001T patent/SMT202500001T1/it unknown
- 2014-08-26 DK DK14761702.1T patent/DK3038654T3/da active
- 2014-08-26 EP EP19202854.6A patent/EP3626270B1/en active Active
- 2014-08-26 RS RS20241359A patent/RS66371B1/sr unknown
- 2014-08-26 EP EP24206614.0A patent/EP4512397A3/en active Pending
- 2014-08-26 PL PL14761702T patent/PL3038654T3/pl unknown
- 2014-08-26 HU HUE19202854A patent/HUE064634T2/hu unknown
- 2014-08-26 PL PL19202854.6T patent/PL3626270T3/pl unknown
- 2014-08-26 HR HRP20200060TT patent/HRP20200060T1/hr unknown
- 2014-08-26 HR HRP20240034TT patent/HRP20240034T1/hr unknown
- 2014-08-26 DK DK19202854.6T patent/DK3626270T3/da active
- 2014-08-26 HU HUE23202190A patent/HUE069419T2/hu unknown
2020
- 2020-01-28 CY CY20201100075T patent/CY1122531T1/el unknown
- 2020-11-24 US US17/103,327 patent/US20210077461A1/en active Pending

Also Published As

Publication number	Publication date
HRP20240034T1 (hr)	2024-03-29
EP4512397A2 (en)	2025-02-26
SI3038654T1 (sl)	2020-02-28
PL3038654T3 (pl)	2020-05-18
PT3626270T (pt)	2024-01-11
RS59816B1 (sr)	2020-02-28
DK3626270T3 (da)	2024-01-15
HRP20200060T1 (hr)	2020-04-03
EP4512397A3 (en)	2025-05-14
PT4321157T (pt)	2025-01-08
EP3626270B1 (en)	2023-10-11
FI4321157T3 (fi)	2025-01-20
LT3038654T (lt)	2020-01-27
JP2016528303A (ja)	2016-09-15
WO2015028941A1 (en)	2015-03-05
PT3038654T (pt)	2020-02-04
HUE047186T2 (hu)	2020-04-28
US20210077461A1 (en)	2021-03-18
EP4321157A2 (en)	2024-02-14
EP4321157A3 (en)	2024-05-15
EP4321157B1 (en)	2024-10-23
ES2767084T3 (es)	2020-06-16
ES3001196T3 (es)	2025-03-04
HUE064634T2 (hu)	2024-04-28
DK4321157T3 (da)	2024-12-16
CY1122531T1 (el)	2021-01-27
LT3626270T (lt)	2024-01-25
ES2968541T3 (es)	2024-05-10
SMT202500001T1 (it)	2025-03-12
EP3626270A1 (en)	2020-03-25
DK3038654T3 (da)	2020-02-03
FI3626270T3 (fi)	2024-01-11
HRP20241763T1 (hr)	2025-03-14
EP3038654B1 (en)	2019-10-30
SI4321157T1 (sl)	2025-03-31
PL4321157T3 (pl)	2025-03-03
SI3626270T1 (sl)	2024-03-29
RS66371B1 (sr)	2025-02-28
EP3038654A1 (en)	2016-07-06
JP6097888B2 (ja)	2017-03-15
LT4321157T (lt)	2025-01-10
RS65037B1 (sr)	2024-02-29
HUE069419T2 (hu)	2025-03-28
US20160213646A1 (en)	2016-07-28

Publication	Publication Date	Title
IL287516A (en)	2021-12-01	Medicinal uses of empagliflozin
HUE064634T2 (hu)	2024-04-28	Kardiovaszkuláris betegségek kezelése
IL241101A0 (en)	2015-11-30	Medicinal uses of empagliflozin
SG11201507121RA (en)	2015-10-29	Treatment of cataplexy
IL241102A0 (en)	2015-11-30	Medicinal uses of empagliflozin
LT2981271T (lt)	2019-01-10	Empagliflozino terapinis panaudojimas
IL241096A0 (en)	2015-11-30	Treatment methods
GB201607581D0 (en)	2016-06-15	Treatment of cancer
GB201320014D0 (en)	2013-12-25	Treatment of cardiovascular disease
GB201321628D0 (en)	2014-01-22	Treatment of disease
GB201314303D0 (en)	2013-09-25	Treatment of HPV
GB201322347D0 (en)	2014-02-05	Treatment of cancer
GB201318742D0 (en)	2013-12-04	Treatment of cancer
GB201308529D0 (en)	2013-06-19	Treatment of cancer
GB201305020D0 (en)	2013-05-01	Treatment of cancer
GB201322778D0 (en)	2014-02-05	Method of treatment
GB201314882D0 (en)	2013-10-02	Method of treatment
GB201219092D0 (en)	2012-12-05	Treatment of cardiovascular disease
GB201320653D0 (en)	2014-01-08	Treatment of plants
GB201216740D0 (en)	2012-10-31	Methods of treatment
GB201216748D0 (en)	2012-10-31	Methods of treatment
GB201206330D0 (en)	2012-05-23	Methods of treatment
GB201206324D0 (en)	2012-05-23	Methods of treatment
GB201206325D0 (en)	2012-05-23	Methods of treatment
GB201206326D0 (en)	2012-05-23	Methods of treatment